Virtual Reality Integration in Ketamine Therapy: US Chart Review Insights

VR Use During Ketamine Therapy Sessions Is Feasible and Tolerated, Chart Review Finds

A retrospective chart review published on October 29, 2026, in Bioengineer.org reports that integrating virtual reality (VR) into ketamine-assisted therapy sessions is both feasible and well-tolerated by patients. The review, conducted at an unnamed US clinical site, analyzed patient records to assess whether VR could be practically and safely incorporated into the therapeutic environment alongside ketamine administration. While the study does not provide prospective or controlled data, it represents one of the first real-world examinations of digital augmentation in psychedelic-assisted therapy settings.

Mechanism and Context: How VR May Influence Psychedelic-Assisted Therapy

Virtual reality (VR) offers immersive, multi-sensory environments that can be tailored to support therapeutic goals during altered states induced by ketamine. In clinical practice, ketamine is administered at sub-anesthetic doses for treatment-resistant depression and other mental health conditions, often in conjunction with psychotherapy. The hypothesis is that VR could enhance the therapeutic setting, reduce anxiety, and guide patient experiences through curated visual and auditory stimuli. According to the chart review, most patients tolerated VR without significant adverse effects, and clinicians were able to implement the technology without major workflow disruptions. Notably, the review found that VR was most commonly used during the onset and plateau phases of ketamine effects, suggesting a potential role in shaping the subjective experience or supporting integration work.

Policy and Research Implications: Early Evidence, but No Efficacy Claims

The feasibility and tolerability findings may encourage further research into digital-psychedelic combinations, but the absence of controlled or prospective data limits clinical and regulatory conclusions. The US Food and Drug Administration (FDA) has not issued guidance on the use of VR in conjunction with psychedelic-assisted therapy, and current clinical trial registries (e.g., ClinicalTrials.gov) list few, if any, ongoing studies formally evaluating this combination. The chart review's retrospective design means it cannot establish efficacy, safety, or best practices, but it does provide a foundation for designing future randomized controlled trials (RCTs). For clinics and digital therapeutics developers, these results may inform protocol development and risk assessment, but commercial deployment should proceed with caution pending more robust evidence.

• Regulatory Uncertainty: Without FDA or state-level guidance, clinics face legal ambiguity in offering VR-augmented psychedelic therapy.
• Intellectual Property (IP) Considerations: Early adoption may influence future IP claims around digital-psychedelic protocols, a non-obvious implication for operators and investors.

Risks, Unknowns, and Potential Failure Modes

While the chart review suggests VR is generally tolerated, it does not capture rare adverse events, long-term effects, or the impact on therapeutic outcomes. Potential risks include exacerbation of dissociation, cybersickness, or interference with therapeutic rapport. The lack of standardized VR content and protocols introduces variability that could affect both safety and efficacy. A concrete failure mode not widely discussed is the risk of over-reliance on digital environments at the expense of human connection, which may undermine key elements of psychedelic therapy. Furthermore, retrospective chart reviews are susceptible to selection and reporting biases, limiting generalizability.

Looking Forward: Next Steps for Research and Clinical Practice

Prospective, controlled studies are needed to determine whether VR meaningfully enhances, detracts from, or has no effect on the outcomes of ketamine-assisted therapy. Stakeholders should monitor developments from academic centers, digital health companies, and regulatory agencies. As the field advances, questions around standardization, safety monitoring, and patient selection will become increasingly important. The integration of VR and psychedelics represents a frontier for both clinical innovation and regulatory scrutiny, and early adopters may shape the standards for digital-psychedelic therapeutics in the coming years.

How we research: This article was written and reviewed by Dr. Alex R. Jensen, PhD (neuroscience, clinical trials editor) on 2026-10-30. Primary source: Bioengineer.org, 2026-10-29.